Andrx’ ANDAs on hold
This article was originally published in The Tan Sheet
Executive Summary
FDA has placed Andrx in "Official Action Indicated" status, thus placing all of the firm's abbreviated new drug applications are on hold, the company announces Sept. 6. The action followed an FDA inspection of Andrx' manufacturing facilities that ended in May 2005 and resulted in the issuance of a "Form 483." The company says it had responded to FDA, and included a proposed corrective action plan in its response. The agency has not yet commented on either the response or the corrective action plan, the company said. According to its second-quarter 10-Q filing Andrx has approximately 30 ANDAs pending at FDA...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.